Oncolytics Biotech Inc.

499 articles with Oncolytics Biotech Inc.

• Oncolytics Biotech® Announces Clinical and Biomarker Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Checkpoint Inhibitor Combination in Pancreatic Cancer

  5/20/2021

  The study achieved a 42% disease control rate in difficult-to-treat, second-line pancreatic cancer patients despite the absence of chemotherapy in the treatment regimen Pelareorep and pembrolizumab synergize to generate anti-cancer immune responses in patients showing disease control Clinical response was associated with increased activation of anti-cancer CD8+ T cells

• Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference

  5/13/2021

  Oncolytics Biotech® Inc. announced that the Company will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference, which is taking place virtually from May 18-20, 2021.

• Oncolytics Biotech® Reports 2021 First Quarter Development Highlights and Financial Results

  5/7/2021

  Oncolytics Biotech today announced its financial results and development highlights for the quarter ended March 31, 2021.

• Oncolytics Biotech® Announces Annual General Meeting

  4/30/2021

  - Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), (the " Company ") today announced that its upcoming 2021 Annual General Meeting (the " Meeting ") will be held virtually at 12:00 p.m. Eastern Daylight Time

• Oncolytics Biotech® Announces Upcoming Presentation at the American Society of Clinical Oncology Annual Meeting

  4/29/2021

  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the acceptance of an abstract discussing its pancreatic adenocarcinoma trial at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021.

• Oncolytics Biotech® Presents Preclinical Data on Pelareorep-based Combination Therapies at the AACR Annual Meeting

  4/12/2021

  - Pelareorep enhances anti-tumor efficacy of PARP-1 and CDK 4/6 inhibitors in preclinical models through a novel immunological mechanism not typically associated with PARP-1 and CDK 4/6 inhibitors

• Oncolytics Biotech® and SOLTI Achieve Primary Endpoint in AWARE-1 Study

  4/12/2021

  - Pelareorep and atezolizumab synergize the anti-cancer immune response in HR+/HER2- breast cancer patients - Pelareorep alone and with checkpoint blockade converts tumors to PD-L1 positive classification - Oncolytics validates that pelareorep significantly improves immunotherapies

• Oncolytics Biotech® to Participate in a Panel Discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference

  4/8/2021

   Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey , the Company's President and Chief Executive Officer, will be participating in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference.

• Oncolytics Biotech® to Host Key Opinion Leader Webinar to Discuss AWARE-1 Data, the Immunotherapeutic Effects of Pelareorep in Breast Cancer, and its Synergistic Activity with CAR T Cells in Solid Tumors

  4/5/2021

  Oncolytics Biotech® Inc. announced that it will host a Key Opinion Leader webinar discussing AWARE-1 data, the immunotherapeutic effects of pelareorep in breast cancer, and its synergistic activity with CAR T cells in solid tumors.

• Oncolytics Biotech® Announces Upcoming Presentations at the AACR Annual Meeting

  3/10/2021

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that it will present updated clinical data from its AWARE-1 window-of-opportunity study in patients with early-stage breast cancer, as well as results from preclinical studies evaluating pelareorep-based combination therapies

• Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Operational Highlights

  2/26/2021

  Conference call and webcast to take place on Friday, March 5, 2021 at 8:30 am ET

• Oncolytics Biotech® Reports Preclinical Data Demonstrating the Synergistic Anti-cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors

  2/23/2021

  Mayo Clinic shows pelareorep vastly improved persistence and efficacy of CAR T cell therapy leading to cures in this model Pelareorep's synergistic effects with CAR T therapy appear to be specific and were not observed with the oncolytic virus VSV

• Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium

  12/9/2020

  - Pelareorep strongly increases CelTIL score, the primary endpoint and a measure of tumor cellularity and inflammation associated with favorable clinical outcomes - Pelareorep increased tumor PD-L1 expression 105-fold, thereby making the tumors more amenable to immuno-checkpoint inhibitor treatment

• Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting

  11/19/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM).

• Oncolytics Biotech® to Present AWARE-1 Data and Provide Updates on Phase 2 BRACELET-1 and IRENE Trials at the 2020 San Antonio Breast Cancer Symposium

  11/17/2020

  Oncolytics Biotech ®  Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of three abstracts for electronic poster presentations to be given as part of the 2020 San Antonio Breast Cancer Symposium, which is being held virtually from December 8-11, 2020 . Details on the abstracts and cor

• Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results

  11/11/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced its financial results and operational highlights for the quarter ended September 30, 2020.

• Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting

  11/9/2020

  - Data from a phase 1b, investigator-sponsored study show that a pelareorep-based combination therapy is safe and well-tolerated in newly diagnosed glioblastoma multiforme patients

• Oncolytics Biotech® and SOLTI Present Clinical Breast Cancer Data Highlighting Pelareorep-Induced Anti-Tumor T Cell Responses at The Society for Immunotherapy of Cancer Annual Meeting

  11/9/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Breast Cancer Research today announced the publication of an electronic poster with clinical data from the AWARE-1 window-of-opportunity breast cancer study at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting.

• Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Operational Highlights

  11/6/2020

  Conference call and webcast to take place on Wednesday, November 11, 2020 at 5:00 pm ET

• Oncolytics Biotech® Collaborates with Roche and AIO to Initiate a Phase 1/2 Gastrointestinal Cancer Trial Combining Pelareorep with Roche's Anti-PD-L1 Checkpoint Inhibitor

  10/27/2020

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced a new multi-indication gastrointestinal (GI) cancer study to be managed by AIO, a leading academic cooperative medical oncology group based in Germany.